Dr. Korn joined Caris Life Sciences in September 2017 as Chief Medical Officer. In this role, Dr. Korn guides Caris’ research efforts and clinical strategies for innovative precision medicine tools and tumor profiling services. His executive oversight responsibilities include medical affairs, evidence curation and collaborative research projects, in particular with the Caris Precision Oncology Alliance. This work has resulted in publication of over 175 posters/presentations at major medical conferences and 129 peer-reviewed publications since fall 2017.
Dr. Korn has an extensive career in cancer research and clinical oncology. He has long-standing research experience in comprehensive molecular tumor profiling and integration of these techniques in clinical practice. He has authored more than 75 peer-reviewed publications and his research on signal transduction and systems biology of cancer has been funded by the NIH and DoD since 2003. Dr. Korn served on the Esophago-Gastric Task Force of the NCI GI Steering Committee and the National Comprehensive Cancer Network (NCCN) Esophageal and Gastric Cancer Panel until 2017.
Dr. Korn is also Professor Emeritus of Medicine and a gastrointestinal oncologist in the Division of Hematology/Oncology at the University of California, San Francisco (UCSF). He founded the Molecular Oncology Initiative at UCSF’s Helen Diller Family Comprehensive Cancer Center (HDFCCC), and initiated and chaired the UCSF Molecular Tumor Board, which is a cross-disciplinary platform supporting clinical decision making based on Next-Generation Sequencing results.
Dr. Korn received his M.D. from Philipps University of Marburg, Germany. He performed his internal medicine and gastroenterology training at Ev. Krankenhaus Dinslaken, Germany, and his medical oncology training at the West German Cancer Center, University of Essen, Germany. He completed postdoctoral training with Dr. Frank McCormick at UCSF.